Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/3/2025

Management of Perforated Peptic Ulcer Peritonitis

Introduction

  • Perforated peptic ulcer peritonitis is a serious condition that requires prompt treatment, including broad-spectrum antibiotics and surgical intervention, as recommended by the World Journal of Emergency Surgery guidelines 1, 2

Antibiotic Therapy

  • Broad-spectrum antibiotics covering gram-positive, gram-negative, and anaerobic bacteria should be started as soon as possible after diagnosis of perforation, with a recommended duration of short-course (3-5 days or until inflammatory markers normalize) 1, 3, 2
  • First-line therapy recommendations include Beta-lactam/beta-lactamase inhibitor combinations (e.g., piperacillin-tazobactam, ampicillin-sulbactam) due to their activity against common pathogens in intra-abdominal infections, as suggested by the World Journal of Emergency Surgery guidelines 1
  • Collection of peritoneal fluid samples for both bacterial and fungal cultures is strongly recommended before starting antibiotics, as suggested by the World Journal of Emergency Surgery 1, 2
  • Adjust antimicrobial therapy based on culture results using a de-escalation approach, as recommended by the World Journal of Emergency Surgery guidelines 1
  • Consider broader coverage when risk factors such as healthcare-associated infection, prior hospitalization, previous antimicrobial therapy, corticosteroid use, organ transplantation, or baseline pulmonary or hepatic disease are present, according to the World Journal of Emergency Surgery 1

Antifungal Therapy

  • Antifungal therapy with fluconazole is not recommended for routine use in patients with stool in the abdomen due to bowel perforation, and should be reserved only for critically ill patients, severely immunocompromised individuals, or those with positive fungal cultures and clinical deterioration 1
  • Antifungal therapy should be considered only in patients with critical illness (shock on admission, APACHE score >20), severe immunocompromise, hospital-acquired infections, or positive fungal cultures with clinical deterioration 1
  • The World Journal of Emergency Surgery guidelines (2020) specifically state that antifungal therapy does not benefit most patients with perforated peptic ulcer peritonitis with Candida isolated from peritoneal fluid 1
  • Fluconazole may be appropriate in specific scenarios, such as in critically ill patients with shock or high APACHE scores (>20), or for severely immunocompromised patients 1
  • For Candida albicans infections, fluconazole is an appropriate choice 4
  • For fluconazole-resistant Candida species, an echinocandin (caspofungin, micafungin, or anidulafungin) is recommended 4
  • In critically ill patients, an echinocandin is preferred over a triazole for initial treatment 4
  • Amphotericin B is not recommended as initial therapy due to toxicity 4
  • Voriconazole or lipid-based amphotericin B formulations are recommended for treatment of invasive aspergillosis 5
  • Posaconazole is recommended as salvage therapy for invasive aspergillosis 5

Antifungal Agents and Dosage

Antifungal Agent Indication Dose
Amphotericin B deoxycholate Invasive candidiasis 0.5-1.0 mg/kg/day
Cryptococcosis 0.7-1.0 mg/kg/day
Invasive aspergillosis 1.0-1.5 mg/kg/day
Lipid-based amphotericin B Invasive candidiasis and aspergillosis 3-5 mg/kg/day
Cryptococcosis 4-6 mg/kg/day
Fluconazole (loading) 800 mg (12 mg/kg) on day 1
Fluconazole (maintenance) Invasive candidiasis 400 mg (6 mg/kg) daily
Caspofungin 70 mg (loading), then 50 mg daily
Voriconazole (loading) 400 mg (6 mg/kg) every 12 hours on day 1
Voriconazole (maintenance) 200 mg (3-4 mg/kg) twice daily

Patient Risk Factors

  • On multivariate analysis, only shock on admission and APACHE score >20 were independent risk factors for poor outcomes 1
  • Patients with critical illness, severe immunocompromise, or hospital-acquired infections may require antifungal therapy 1
  • Critically ill patients (e.g., shock on admission, APACHE score >20) may also benefit from antifungal therapy, as suggested by the World Journal of Emergency Surgery 1

Treatment Approach

  • Source control through surgical intervention remains paramount for successful treatment, and delayed source control is more detrimental than delayed antifungal therapy in most cases 1
  • Fungal colonization does not always indicate infection requiring treatment, and antifungal therapy should be reserved for high-risk patients with specific indications 1
  • In patients with severe immunodeficiency, such as those undergoing allogeneic hematopoietic stem cell transplantation or with graft-versus-host disease, prophylactic antifungal treatment is recommended 6
  • The Infectious Diseases Society of America recommends that antifungal therapy for invasive candidiasis be guided by the patient's risk factors, clinical presentation, and culture results 4
  • Surgical options may include primary repair, resection with anastomosis, or resection with colostomy, depending on the patient's hemodynamic status, degree of contamination, time since perforation, and underlying pathology of the colon 1

Special Considerations

  • In pregnant women, amphotericin B deoxycholate is the preferred treatment option 6
  • In neutropenic patients, removal of central venous catheters should be considered on a case-by-case basis 6
  • Recovery from neutropenia is the most important factor affecting treatment outcome 7
  • All cases of cryptococcosis should be treated, and immunosuppressive therapy should be reduced; prioritizing reduction of corticosteroid dose should be considered 8
  • Antifungal susceptibility testing should be considered in cases of treatment failure or prior antifungal exposure 6
  • Monotherapy with flucytosine should be avoided due to rapid development of resistance 6
  • For candidemia, follow-up blood cultures should be performed 48-72 hours after antifungal treatment and every 2 days thereafter to determine when candidemia has been cleared 6

Monitoring and Adjusting Therapy

  • Monitor clinical response and inflammatory markers to guide therapy duration, and consider repeat cultures if clinical deterioration occurs despite appropriate therapy, according to the World Journal of Emergency Surgery guidelines 1
  • Assess clinical response and inflammatory markers, and adjust therapy accordingly, based on World Journal of Emergency Surgery guidelines 1